China Biologic Products, Inc. (NASDAQ:CBPO) has earned an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $131.67 for the company and are forecasting that the company will post $1.30 EPS for the current quarter, according to Zacks. Zacks has also given China Biologic Products an industry rank of 159 out of 265 based on the ratings given to related companies.
A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC restated a “buy” rating on shares of China Biologic Products in a research report on Friday, August 4th. BidaskClub downgraded China Biologic Products from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research report on Monday, August 7th.
Shares of China Biologic Products (NASDAQ:CBPO) traded down 14.99% on Thursday, hitting $82.59. The stock had a trading volume of 1,488,845 shares. China Biologic Products has a 52 week low of $82.29 and a 52 week high of $125.99. The firm has a 50 day moving average price of $93.45 and a 200-day moving average price of $103.23. The company has a market cap of $2.25 billion, a price-to-earnings ratio of 21.50 and a beta of 1.75.
China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.30 by $0.05. China Biologic Products had a return on equity of 21.86% and a net margin of 31.55%. The firm had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. During the same quarter in the previous year, the company posted $1.26 EPS. The business’s revenue for the quarter was down 2.3% compared to the same quarter last year. Analysts anticipate that China Biologic Products will post $4.95 EPS for the current year.
About China Biologic Products
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about China Biologic Products Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for China Biologic Products Inc. and related companies.